Incidence and risk for neutropenia/agranulocytosis among clozapine users: A retrospective cohort study

International Journal of Psychiatry in Clinical Practice

Volumn 14, Issue 2, 2010, Pages 109-115

  Ratanajamit, Chaveewan ^a   Musakopas, Chutima ^a   Vasiknanonte, Sorayut ^a   Reanmongkol, Wantana ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Agranulocytosis; Clozapine; Cohort; Neutropenia; Psychosis; Valproic acid

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; LITHIUM SALT; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; TICLOPIDINE; VALPROIC ACID;

ADULT; AGED; AGRANULOCYTOSIS; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 77953180077     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651500903402450     Document Type: Article

References (40)

1. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008;23:27-41.
2. Alvir JM, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994;55(Suppl B):137-8.
3. Copolov DL, Bell WR, Benson WJ, Keks NA, Strazzeri DC, Johnson GF. Clozapine treatment in Australia: a review of haematological monitoring. Med J Aust 1998;168:495-7.
4. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996;169:483-8.
5. Kang BJ, Cho MJ, Oh JT, Lee Y, Chae BJ, Ko J. Long-term patient monitoring for clozapine-induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS? Hum Psychopharmacol 2006;21:387-91.
6. Andres E, Maloisel F. Idiosyncratic drug-induced agranu-locytosis or acute neutropenia. Curr Opin Hematol 2008; 15:15-21.
7. Tohen M, Castillo J, Baldessarini RJ, Zarate C, Kando JC. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 1995;152:413-8.
8. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD-10). 2nd ed. Geneva: WHO; 2004.
9. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. New Engl J Med 1993;329:162-7.
10. Andersohn F, Konzen C, Garbe E. Systematic review: agran-ulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2007;146:657-65.
11. Bourin M, Guitton B, Dailly E, Hery P, Jolliet P. A follow-up study of a population of schizophrenic patients treated with clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:1481-95.
12. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999;175:576-80.
13. Imbarlina MJ, Sarkar S, Marwah S, Parepally H, Johnston PR, Brar JS, et al. Leukopenia in clozapine treated patients may be induced by other drugs: a case series. Eur Psychiatry 2004;19:506-9.
14. Senechal A, Landry P, Deschamps R, Lessard M. Neutropenia in a patient treated with clozapine in combination with other psychotropic drugs. Encephale 2002;28:567-9.
15. Madeb R, Hirschmann S, Kurs R, Turkie A, Modai I. Combined clozapine and valproic acid treatment-induced agranulocytosis. Eur Psychiatry 2002;17:238-9.
16. Pantelis C, Adesanya A. Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aust NZ J Psychiatry 2001;35:544-5.
17. Lambertenghi DG. Blood dyscrasias in clozapine-treated patients in Italy. Haematologica 2000;85:233-7.
18. Tantanokij S. Clozapine-induced white blood count disorders in psychiatric patients at Sritunya hospital [dissertation]. Nakhon Pathom: Silpakorn University; 2004.
19. Zhang M, Owen RR, Pope SK, Smith GR. Cost-effectiveness of clozapine monitoring after the first 6 months. Arch Gen Psychiatry 1996;53:954-8.
20. Maskasame S, Krisanaprakornkit T, Khiewyoo J. The incidence of clozapine-induced leukopenia in patients with schizophrenia at Srinagarind Hospital. J Med Assoc Thai 2007;90:2175-80.
21. Udomratn P. Incidence of leukopenia and agranulocytosis in 239 Thai patients treated with clozapine. J Psychiatr Assoc Thai 2000;45:229-36.
22. Adityanjee. Modification of clozapine-induced leukopenia and neutropenia with lithium carbonate. Am J Psychiatry 1995;152:648-9.
23. Blier P, Slater S, Measham T, Koch M, Wiviott G. Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacol 1998;13:137-40.
24. Brunoni AR, Kobuti Ferreira LR, Gallucci-Neto J, Elkis H, Vinicius ZM, Velloso ED. Lithium as a treatment of clozapine-induced neutropenia: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:2006-7.
25. Esposito D, Hardy P, Corruble E. Lithium treatment of clozapine induced neutropenia. Encephale 2005;31:520.
26. Papetti F, Darcourt G, Giordana JY, Spreux A, Thauby S, Feral F, et al. Treatment of clozapine-induced granulocyto-penia with lithium (two observations). Encephale 2004;30: 578-82.
27. Silverstone PH. Prevention of clozapine-induced neutropenia by pretreatment with lithium. J Clin Psychopharmacol 1998;18:86-8.
28. Valevski A, Modai I, Lahav M, Weizman A. Clozapine-lithium combined treatment and agranulocytosis. Int Clin Psychopharmacol 1993;8:63-5.
29. Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. J Clin Psychiatry 2006;67: 756-60.
30. Sporn A, Gogtay N, Ortiz-Aguayo R, Alfaro C, Tossell J, Lenane M, et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003;13:401-4.
31. Caetano D. Adjunctive medication effects may increase risk for neutropenia. Am J Psychiatry 2008;165:1611-2.
32. Imbarlina MJ, Sarkar S, Marwah S, Parepally H, Johnston PR, Brar JS, et al. Leukopenia in clozapine treated patients may be induced by other drugs: a case series. Eur Psychiatry 2004;19:506-9.
33. Madeb R, Hirschmann S, Kurs R, Turkie A, Modai I. Combined clozapine and valproic acid treatment-induced agranulocytosis. Eur Psychiatry 2002;17:238-9.
34. Pantelis C, Adesanya A. Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine. Aust NZ J Psychiatry 2001;35:544-5.
35. Facciola G, Avenoso A, Scordo MG, Madia AG, Ventimiglia A, Perucca E, et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit 1999;21:341-5.
36. Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994;36:487-8.
37. Longo LP, Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine. Am J Psychiatry 1995;152:650.
38. Branik E, Nitschke M. Pericarditis and polyserositis as a side effect of clozapine in an adolescent girl. J Child Adolesc Psychopharmacol 2004;14:311-4.
39. Fitzsimons J, Berk M, Lambert T, Bourin M, Dodd S. A review of clozapine safety. Expert Opin Drug Saf 2005; 4:731-44.
40. Roh S, Ahn DH, Nam JH, Yang BH, Lee BH, Kim YS. Cardiomyopathy associated with clozapine. Exp Clin Psycho-pharmacol 2006;14:94-8.